Base de dados : MEDLINE
Pesquisa : D02.540.576.500.992 [Categoria DeCS]
Referências encontradas : 12139 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1214 ir para página                         

  1 / 12139 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29317655
[Au] Autor:Pawlowski AC; Stogios PJ; Koteva K; Skarina T; Evdokimova E; Savchenko A; Wright GD
[Ad] Endereço:Michael G. DeGroote Institute for Infectious Disease Research and the Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, L8S 4L8, ON, Canada.
[Ti] Título:The evolution of substrate discrimination in macrolide antibiotic resistance enzymes.
[So] Source:Nat Commun;9(1):112, 2018 01 09.
[Is] ISSN:2041-1723
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The production of antibiotics by microbes in the environment and their use in medicine and agriculture select for existing and emerging resistance. To address this inevitability, prudent development of antibiotic drugs requires careful consideration of resistance evolution. Here, we identify the molecular basis for expanded substrate specificity in MphI, a macrolide kinase (Mph) that does not confer resistance to erythromycin, in contrast to other known Mphs. Using a combination of phylogenetics, drug-resistance phenotypes, and in vitro enzyme assays, we find that MphI and MphK phosphorylate erythromycin poorly resulting in an antibiotic-sensitive phenotype. Using likelihood reconstruction of ancestral sequences and site-saturation combinatorial mutagenesis, supported by Mph crystal structures, we determine that two non-obvious mutations in combination expand the substrate range. This approach should be applicable for studying the functional evolution of any antibiotic resistance enzyme and for evaluating the evolvability of resistance enzymes to new generations of antibiotic scaffolds.
[Mh] Termos MeSH primário: Proteínas de Bactérias/metabolismo
Farmacorresistência Bacteriana
Macrolídeos/metabolismo
Fosfotransferases/metabolismo
[Mh] Termos MeSH secundário: Antibacterianos/química
Antibacterianos/metabolismo
Antibacterianos/farmacologia
Proteínas de Bactérias/química
Proteínas de Bactérias/genética
Eritromicina/química
Eritromicina/metabolismo
Eritromicina/farmacologia
Escherichia coli/efeitos dos fármacos
Escherichia coli/genética
Macrolídeos/química
Macrolídeos/farmacologia
Modelos Moleculares
Estrutura Molecular
Fosfotransferases/classificação
Fosfotransferases/genética
Filogenia
Domínios Proteicos
Especificidade por Substrato
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Bacterial Proteins); 0 (Macrolides); 63937KV33D (Erythromycin); EC 2.7.- (Phosphotransferases)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE
[do] DOI:10.1038/s41467-017-02680-0


  2 / 12139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29226307
[Au] Autor:Romero L; Huerfano C; Grillo-Ardila CF
[Ad] Endereço:Department of Obstetrics and Gynecology, Faculty of Medicine, Universidad Nacional de Colombia, Bogota, Colombia.
[Ti] Título:Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults.
[So] Source:Cochrane Database Syst Rev;12:CD012492, 2017 Dec 11.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Chancroid is a genital ulcerative disease caused by Haemophilus ducreyi. This microorganism is endemic in Africa, where it can cause up to 10% of genital ulcers. Macrolides may be an effective alternative to treat chancroid and, based on their oral administration and duration of therapy, could be considered as first line therapy. OBJECTIVES: To assess the effectiveness and safety of macrolides for treatment of H ducreyi infection in sexually active adults. SEARCH METHODS: We searched the Cochrane STI Group Specialized Register, CENTRAL, MEDLINE, Embase, LILACS, WHO ICTRP, ClinicalTrials.gov and Web of Science to 30 October 2017. We also handsearched conference proceedings and reference lists of retrieved studies. SELECTION CRITERIA: Randomized controlled trials (RCTs) comparing macrolides in different regimens or with other therapeutic alternatives for chancroid. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trials for inclusion, extracted data and assessed risk of bias. We resolved disagreements through consensus. We used the GRADE approach to assess the quality of the evidence. MAIN RESULTS: Seven RCTs (875 participants) met our inclusion criteria, of which four were funded by industry. Five studies (664 participants) compared macrolides with ceftriaxone, ciprofloxacin, spectinomycin or thiamphenicol. Low quality evidence suggested there was no difference between the groups after treatment in terms of clinical cure (risk ratio (RR) 1.09, 95% confidence interval (CI) 0.97 to 1.21; 2 studies, 340 participants with syndromic approach and RR 1.06, 95% CI 0.98 to 1.15; 5 studies, 348 participants with aetiological diagnosis) or improvement (RR 0.89, 95% CI 0.52 to 1.52; 2 studies, 340 participants with syndromic approach and RR 0.80, 95% CI 0.42 to 1.51; 3 studies, 187 participants with aetiological diagnosis). Based on low and very low quality evidence, there was no difference between macrolides and any other antibiotic treatments for microbiological cure (RR 0.93, 95% CI 0.74 to 1.16; 1 study, 45 participants) and minor adverse effects (RR 1.34, 95% CI 0.24 to 7.51; 3 studies, 412 participants).Two trials (269 participants) compared erythromycin with any other macrolide type. Low quality evidence suggested that, compared with azithromycin or rosaramicin, long courses of erythromycin did not increase clinical cure (RR 1.00, 95% CI 0.91 to 1.10; 2 studies, 269 participants with syndromic approach and RR 1.04, 95% CI 0.93 to 1.16; 2 studies, 211 participants with aetiological diagnosis), with a similar frequency of minor adverse effects between the groups (RR 1.14, 95% CI 0.63 to 2.06; 1 trial, 101 participants). For this comparison, subgroup analysis found no difference between HIV-positive participants (RR 1.02, 95% CI 0.73 to 1.43; 1 study, 38 participants) and HIV-negative participants (RR 1.04, 95% CI 0.94 to 1.14; 1 study, 89 participants). We downgraded the quality of evidence to low, because of imprecision, some limitations on risk of bias and heterogeneity.None of the trials reported serious adverse events, cost effectiveness and participant satisfaction. AUTHORS' CONCLUSIONS: At present, the quality of the evidence on the effectiveness and safety of macrolides for treatment of H ducreyi infection in sexually active adults is low, implying that we are uncertain about the estimated treatment effect. There is no statistically significant difference between the available therapeutic alternatives for the treatment of sexually active adults with genital ulcers compatible with chancroid. Low quality evidence suggests that azithromycin could be considered as the first therapeutic alternative, based on their mono-dose oral administration, with a similar safety and effectiveness profile, when it is compared with long-term erythromycin use.Due to sparse available evidence about the safety and effectiveness of macrolides to treat H ducreyi infection in people with HIV, these results should be taken with caution.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Cancroide/tratamento farmacológico
Haemophilus ducreyi
Macrolídeos/uso terapêutico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Azitromicina/uso terapêutico
Eritromicina/efeitos adversos
Eritromicina/uso terapêutico
Seres Humanos
Leucomicinas/uso terapêutico
Macrolídeos/efeitos adversos
Meia-Idade
Ensaios Clínicos Controlados Aleatórios como Assunto
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Leucomycins); 0 (Macrolides); 63937KV33D (Erythromycin); 83905-01-5 (Azithromycin); E907BNQ7SH (rosaramicin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180123
[Lr] Data última revisão:
180123
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD012492.pub2


  3 / 12139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28471562
[Au] Autor:Ulanovsky I; Shnaider M; Geffen Y; Smolkin T; Mashiah T; Makhoul IR
[Ad] Endereço:Department of Neonatology, Rappaport Children's Hospital, Rambam Health Care Campus, affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
[Ti] Título:Erythromycin Prophylaxis for Neonatal Conjunctivitis: Ointment Versus Drops.
[So] Source:Isr Med Assoc J;18(7):404-406, 2016 Jul.
[Is] ISSN:1565-1088
[Cp] País de publicação:Israel
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Due to a shortage of individualized erythromycin ointment (IEO), we switched to shared erythromycin drops (SED). Following this change, nurses claimed observing more cases of eye discharge. OBJECTIVES: To test whether switching from IEO to SED affected the rate of neonatal conjunctivitis (NC). METHODS: The study group included 14,916 neonates > 35 weeks of gestation, further divided into two birth periods of 12 months each: 1 January 2013 to 31 December 2013 (IEO) and 1 February 2014 to 31 January 2015 (SED). We compared the two birth periods with regard to three variables: clinical NC (number of conjunctival swabs/1000 neonates), bacterial NC (number of culture-positive swabs/1000 neonates), and bacterial growth percentage (number of culture-positive swabs/100 samples). RESULTS: Compared to 2012-2013, the period 2014-2015 included fewer cesarean deliveries and shorter length of stay (LOS). Clinical NC, bacterial NC and bacterial-growth percentage were not different between the two periods. Variables that were independently significantly associated with increased clinical NC included male gender (OR 1.48, CI 1.21-1.81) and LOS (OR 1.24, CI 1.18-1.29). LOS was associated with bacterial NC (OR 1.19, CI 1.11-1.28). Coagulase-negative staphylococci, Escherichia coli and Pseudomonas aeruginosa were the prevalent pathogens, though without difference between periods. CONCLUSIONS: Rates of clinical NC, bacterial NC and bacterial-growth percentage were not different between the study periods. Switching from IEO to SED had no effect on the NC rate.
[Mh] Termos MeSH primário: Antibacterianos/administração & dosagem
Cesárea/estatística & dados numéricos
Eritromicina/administração & dosagem
Oftalmia Neonatal/prevenção & controle
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Recém-Nascido
Tempo de Internação
Masculino
Pomadas
Oftalmia Neonatal/epidemiologia
Oftalmia Neonatal/microbiologia
Soluções Oftálmicas
Gravidez
Estudos Retrospectivos
Fatores de Risco
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Ointments); 0 (Ophthalmic Solutions); 63937KV33D (Erythromycin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE


  4 / 12139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28917836
[Au] Autor:Tran LTC; Gueutin C; Frebourg G; Burucoa C; Faivre V
[Ad] Endereço:Institut Galien Paris-Sud, CNRS, Université Paris-Saclay, Univ. Paris-Sud, 5, rue Jean-Baptiste Clément, Châtenay-Malabry 92296, France.
[Ti] Título:Erythromycin encapsulation in nanoemulsion-based delivery systems for treatment of Helicobacter pylori infection: Protection and synergy.
[So] Source:Biochem Biophys Res Commun;493(1):146-151, 2017 Nov 04.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Poorly water-soluble and unstable compounds are difficult to develop as drug products using conventional formulation techniques. The aim of the present study was to develop and evaluate a nanoformulation prepared by a hot high-pressure homogenization method, which was a scalable and solvent-free process. We successfully prepared stable nanodispersions to protect a labile antibiotic, erythromycin. The mean diameter of the dispersed droplets was approximately 150 nm, and size distribution was unimodal. Dispersion was physically stable at room temperature for over six months. Using erythromycin as a model compound, we studied its antimicrobial activity in vitro on Helicobacter pylori. Results showed that drug encapsulation improves API stability in an acidic environment and is conducive to a synergistic effect between the drug and the formulation.
[Mh] Termos MeSH primário: Apoptose/efeitos dos fármacos
Preparações de Ação Retardada/administração & dosagem
Eritromicina/administração & dosagem
Helicobacter pylori/efeitos dos fármacos
Nanocápsulas/administração & dosagem
Nanocápsulas/química
[Mh] Termos MeSH secundário: Antibacterianos/administração & dosagem
Antibacterianos/química
Apoptose/fisiologia
Preparações de Ação Retardada/química
Difusão
Composição de Medicamentos/métodos
Estabilidade de Medicamentos
Emulsões/química
Eritromicina/química
Helicobacter pylori/citologia
Helicobacter pylori/fisiologia
Nanocápsulas/ultraestrutura
Tamanho da Partícula
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Delayed-Action Preparations); 0 (Emulsions); 0 (Nanocapsules); 63937KV33D (Erythromycin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170918
[St] Status:MEDLINE


  5 / 12139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28841421
[Au] Autor:Tintino SR; Morais-Tintino CD; Campina FF; Costa MDS; Menezes IRA; de Matos YMLS; Calixto-Júnior JT; Pereira PS; Siqueira-Junior JP; Leal-Balbino TC; Coutinho HDM; Balbino VQ
[Ad] Endereço:Laboratory of Microbiology and Molecular Biology (LMBM), Department of Biological Chemistry/CCBS/URCA, Brazil.
[Ti] Título:Tannic acid affects the phenotype of Staphylococcus aureus resistant to tetracycline and erythromycin by inhibition of efflux pumps.
[So] Source:Bioorg Chem;74:197-200, 2017 Oct.
[Is] ISSN:1090-2120
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The widespread use of antibiotics created selective pressure for the emergence of strains that would persist despite antibiotic toxicity. The bacterial resistance mechanisms are several, with efflux pumps being one of the main ones. These pumps are membrane proteins with the function of removing antibiotics from the cell cytoplasm. Due to this importance, the aim of this work was to evaluate the inhibitory effect of tannic acid against efflux pumps expressed by the Staphylococcus aureus RN4220 and IS-58 strains. The efflux pump inhibition was assayed using a sub-inhibitory concentration of efflux pump standard inhibitors and tannic acid (MIC/8), observing their capacity to decrease the MIC of Ethidium bromide (EtBr) and antibiotics due the possible inhibitory effect of these substances. The MICs of EtBr and antibiotics were significantly different in the presence of tannic acid, indicating the inhibitory effect of this product against efflux pumps of both strains. These results indicate the possible usage of tannic acid asan inhibitor and an adjuvant in the antibiotic therapy against multidrug resistant bacteria (MDR).
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Farmacorresistência Bacteriana/efeitos dos fármacos
Eritromicina/farmacologia
Staphylococcus aureus/efeitos dos fármacos
Taninos/farmacologia
Tetraciclina/farmacologia
[Mh] Termos MeSH secundário: Antibacterianos/química
Relação Dose-Resposta a Droga
Farmacorresistência Bacteriana/genética
Eritromicina/química
Testes de Sensibilidade Microbiana
Estrutura Molecular
Fenótipo
Staphylococcus aureus/genética
Relação Estrutura-Atividade
Taninos/química
Tetraciclina/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Tannins); 63937KV33D (Erythromycin); F8VB5M810T (Tetracycline)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170826
[St] Status:MEDLINE


  6 / 12139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28813477
[Au] Autor:Ji W; Zhang L; Guo Z; Xie S; Yang W; Chen J; Wang J; Cheng Z; Wang X; Zhu X; Wang J; Wang H; Huang J; Liang N; McIver DJ
[Ad] Endereço:Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China.
[Ti] Título:Colonization prevalence and antibiotic susceptibility of Group B Streptococcus in pregnant women over a 6-year period in Dongguan, China.
[So] Source:PLoS One;12(8):e0183083, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This study investigated the prevalence of recto-vaginal Group B Streptococcus (GBS) colonization, serotype distribution, and antimicrobial susceptibility patterns among pregnant women in Dongguan, China. Recto-vaginal swabs were collected from pregnant women at gestational age 35-37 weeks between January 1st 2009 and December 31st 2014. Isolates were serotyped by latex-agglutination and were tested against seven antimicrobials by disk diffusion. Of 7,726 pregnant women who completed GBS testing, 636 (8.2%) were GBS carriers. Of 153 GBS isolates available for typing, 6 serotypes (Ia, Ib, III, V, VI and VIII) were identified with type III being predominant, while 9 (5.9%) were non-typable isolates. All isolates were sensitive to penicillin, ceftriaxone, linezolid and vancomycin, whereas 52.4% were resistant to clindamycin, 25.9% were resistant to levofloxacin and 64.9% were resistant to erythromycin. This study showed the recto-vaginal colonization prevalence of GBS in Dongguan is significant. Due to 100% susceptibility to penicillin of all GBS samples, penicillin remains the first recommendation for treatment and prevention against GBS infection. Susceptibility testing should be performed for women allergic to penicillin in order to choose the most appropriate antibacterial agents for treatment and prevention of vertical transmission to neonates. In addition, we suggest establishing standard processes for GBS culture and identification in China as early as possible.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Infecções Estreptocócicas/microbiologia
Streptococcus agalactiae/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Ceftriaxona/farmacologia
China/epidemiologia
Eritromicina/farmacologia
Feminino
Seres Humanos
Linezolida/farmacologia
Testes de Sensibilidade Microbiana
Meia-Idade
Penicilinas/farmacologia
Gravidez
Prevalência
Infecções Estreptocócicas/epidemiologia
Vancomicina/farmacologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Penicillins); 63937KV33D (Erythromycin); 6Q205EH1VU (Vancomycin); 75J73V1629 (Ceftriaxone); ISQ9I6J12J (Linezolid)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170817
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0183083


  7 / 12139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28715457
[Au] Autor:Wang D; Lin Z; Wang T; Ding X; Liu Y
[Ad] Endereço:State Key Laboratory of Pollution Control and Resource Reuse, College of Environmental Science and Engineering, Tongji University, Shanghai, China.
[Ti] Título:An analogous wood barrel theory to explain the occurrence of hormesis: A case study of sulfonamides and erythromycin on Escherichia coli growth.
[So] Source:PLoS One;12(7):e0181321, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Hormesis has aroused much attention during the past two decades and may have great implications on many fields, including toxicology and risk assessment. However, the observation of hormesis remains challenged under laboratory conditions. To determine favorable conditions under which to observe hormesis, we investigated the hormetic responses of Escherichia coli (E. coli) upon exposure of different concentrations of sulfonamides and erythromycin at different time points and in different culture media: Luria-Bertani (LB) broth and Mueller Hinton (MH) broth. Our results reveal that the antibiotics, both individually and combined, produce hormetic effects on E. coli growth in MH broth at the stationary phase, with the maximum stimulatory response increasing with time. However, in LB broth, the hormetic response was not observed, which can be explained by an analogous "wood barrel theory". Our study suggests that the culture medium and time should be taken into consideration in hormetic studies, and compound mixtures should also receive more attention for their potential to induce hormesis.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Eritromicina/farmacologia
Escherichia coli/efeitos dos fármacos
Escherichia coli/crescimento & desenvolvimento
Hormese
Sulfonamidas/farmacologia
[Mh] Termos MeSH secundário: Meios de Cultura
Escherichia coli/fisiologia
Modelos Biológicos
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Culture Media); 0 (Sulfonamides); 63937KV33D (Erythromycin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170718
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0181321


  8 / 12139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28711353
[Au] Autor:Jia L; Yan M; Shen Y; Qin Y; Qiang S; Ma S
[Ad] Endereço:Department of Medicinal Chemistry Key Laboratory of Chemical Biology (Ministry of Education) School of Pharmaceutical Sciences, Shandong University, a. 44 West Culture Road, Jinan 250012 PR China.
[Ti] Título:Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides.
[So] Source:Bioorg Med Chem Lett;27(16):3693-3697, 2017 08 15.
[Is] ISSN:1464-3405
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A series of novel 11-O-carbamoyl clarithromycin ketolides were designed, synthesized and evaluated for their in vitro antibacterial activity. The results showed that the majority of the target compounds displayed improved activity compared with references against erythromycin-resistant S. pneumoniae A22072 expressing the mef gene, S. pneumoniae B1 expressing the erm gene and S. pneumoniae AB11 expressing the mef and erm genes. In particular, compounds 9, 18, 19 and 22 showed the most potent activity against erythromycin-resistant S. pneumoniae A22072 with the MIC values of 0.5µg/mL. Furthermore, compounds 11, 18, 19, 24 and 29 were also found to exhibit favorable antibacterial activity against erythromycin-susceptible S. pyogenes with the MIC values of 0.125-1µg/mL, and moderate activity against erythromycin-susceptible S. aureus ATCC25923 and B. subtilis ATCC9372.
[Mh] Termos MeSH primário: Antibacterianos/síntese química
Claritromicina/síntese química
Cetolídeos/química
[Mh] Termos MeSH secundário: Antibacterianos/química
Antibacterianos/farmacologia
Proteínas de Bactérias/genética
Proteínas de Bactérias/metabolismo
Claritromicina/análogos & derivados
Claritromicina/farmacologia
Farmacorresistência Bacteriana/efeitos dos fármacos
Eritromicina/farmacologia
Bactérias Gram-Negativas/efeitos dos fármacos
Bactérias Gram-Positivas/efeitos dos fármacos
Proteínas de Membrana/genética
Proteínas de Membrana/metabolismo
Metiltransferases/genética
Metiltransferases/metabolismo
Testes de Sensibilidade Microbiana
Streptococcus pneumoniae/efeitos dos fármacos
Streptococcus pyogenes/efeitos dos fármacos
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Bacterial Proteins); 0 (Ketolides); 0 (MefA protein, Streptococcus); 0 (Membrane Proteins); 63937KV33D (Erythromycin); EC 2.1.1.- (Methyltransferases); EC 2.1.1.184 (ErmA protein, Bacteria); H1250JIK0A (Clarithromycin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171125
[Lr] Data última revisão:
171125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170717
[St] Status:MEDLINE


  9 / 12139 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28693489
[Au] Autor:Adhikari RP; Shrestha S; Barakoti A; Amatya R
[Ad] Endereço:Department of Microbiology, Nepal Medical College and Teaching Hospital, Jorpati, Kathmandu, Nepal. rampd11@yahoo.com.
[Ti] Título:Inducible clindamycin and methicillin resistant Staphylococcus aureus in a tertiary care hospital, Kathmandu, Nepal.
[So] Source:BMC Infect Dis;17(1):483, 2017 Jul 11.
[Is] ISSN:1471-2334
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Staphylococcus aureus, an important nosocomial pathogen, is frequently associated with infections in human. The management of the infections by it especially methicillin resistant ones is often difficult because methicillin resistant S. aureus is usually resistant to multiple antibiotics. Macrolide-lincosamide streptogramin B family of antibiotics is commonly used to treat such infections as an alternative to vancomycin. METHODS: This study was conducted over the period of one and half year from November 2013-April 2015 in Microbiology laboratory of Nepal Medical College and Teaching Hospital, Kathmandu, Nepal to find the incidence of different phenotypes of MLS resistance among S. aureus from clinical samples and their association with methicillin resistance. Two hundred seventy isolates of S. aureus were included in the study. Methicillin resistance was detected by cefoxitin disc diffusion method and inducible clindamycin resistance by erythromycin and clindamycin disc approximation test (D-test). RESULTS: Of the 270 clinical isolates of S. aureus, 25.1% (68/270) were MRSA. Erythromycin and clindamycin resistance was seen in 54.4% (147/270) and 41.8% (113/270) isolates respectively. Resistance to erythromycin and clindamycin were higher in MRSA as compared to MSSA (erythromycin-resistance: 88.2% Vs 39.1% and clindamycin-resistance: 79.4% Vs 41.8%). The overall prevalence of MLS and MLS phenotype was 11.48% (31/270) and 29.25% (79/270) respectively. Both MLS and MLS phenotypes predominated in MRSA strains. CONCLUSIONS: Detection rate of MRSA in our study shows the necessity to improve in healthcare practices and to formulate new policy for the control of MRSA infections. Clindamycin resistance in the form of MLS and MLS especially among MRSA emphasizes the need of D-test to be performed routinely in our set up while using clindamycin as an alternative choice to anti-staphylococcal antibiotics like vancomycin and linezolid in the treatment of staphylococcal infections.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Clindamicina/farmacologia
Farmacorresistência Bacteriana/efeitos dos fármacos
Infecções Estafilocócicas/microbiologia
Staphylococcus aureus/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Antibacterianos/uso terapêutico
Criança
Pré-Escolar
Clindamicina/uso terapêutico
Infecção Hospitalar/microbiologia
Estudos Transversais
Eritromicina/farmacologia
Eritromicina/uso terapêutico
Feminino
Seres Humanos
Lactente
Recém-Nascido
Macrolídeos/farmacologia
Macrolídeos/uso terapêutico
Masculino
Meticilina/farmacologia
Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos
Staphylococcus aureus Resistente à Meticilina/isolamento & purificação
Testes de Sensibilidade Microbiana
Meia-Idade
Nepal/epidemiologia
Prevalência
Staphylococcus aureus/isolamento & purificação
Centros de Atenção Terciária
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Macrolides); 3U02EL437C (Clindamycin); 63937KV33D (Erythromycin); Q91FH1328A (Methicillin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170712
[St] Status:MEDLINE
[do] DOI:10.1186/s12879-017-2584-5


  10 / 12139 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28679429
[Au] Autor:Wang HK; Huang CY; Huang YC
[Ad] Endereço:School of Medicine, Chang Gung University, Gueishan, Taoyuan, Taiwan.
[Ti] Título:Clinical features and molecular characteristics of childhood community-associated methicillin-resistant Staphylococcus aureus infection in a medical center in northern Taiwan, 2012.
[So] Source:BMC Infect Dis;17(1):470, 2017 Jul 05.
[Is] ISSN:1471-2334
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Since first reported in 2002, the rate of methicillin-resistant Staphylococcus aureus (MRSA) among childhood community-associated (CA) S. aureus infection in Taiwan increased significantly up to 2005. There have been no reports on this issue since then. METHODS: We prospectively collected clinical S. aureus isolates from the patients <19 years of age in a university-affiliated hospital in 2012. Only first isolate from each patient was included. The medical records were retrospectively reviewed and the patients were classified as CA or healthcare-associated (HA) by the standard epidemiologic criteria. Isolates as CA-MRSA were further characterized by pulsed-field gel electrophoresis, staphylococcal cassette chromosome (SCCmec) typing, and multilocus sequence typing. RESULTS: A total of 409 S. aureus isolates were included, and 260 (63.6%) were MRSA. The proportion of MRSA among all S. aureus isolates in 2012 increased significantly (p < 0.001) compared to that in 2004-2005. Of the 181 CA-MRSA isolates, 86.2% were identified from pus or wound. Nine pulsotypes were identified with two major types (type D, 119 (65.7%); type C, 27 (14.9%). Most of the isolates carried either SCCmec IV (66 isolates, 36%) or V (112 isolates, 62%). 128 isolates (71%) carried Panton-Valentine leukocidin (PVL) genes. Clonal complex (CC) 59 accounted for 146 isolates (80.7%) of two major pulsotypes, CC45 for 19 isolates, ST30 for 6 isolates and ST8 (USA 300) for 4 isolates. In addition to penicillin (100%), most isolates were resistant to erythromycin (81%) and clindamycin (79.3%). CONCLUSIONS: Around two-thirds of childhood community-associated S. aureus infections in northern Taiwan were MRSA. Though CC59 is still the prevalent community clone, several new clones emerged in northern Taiwan.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Infecções Comunitárias Adquiridas/microbiologia
Staphylococcus aureus Resistente à Meticilina/isolamento & purificação
Infecções Estafilocócicas/etiologia
[Mh] Termos MeSH secundário: Adolescente
Toxinas Bacterianas/genética
Criança
Pré-Escolar
Clindamicina/farmacologia
Infecções Comunitárias Adquiridas/epidemiologia
Eletroforese em Gel de Campo Pulsado
Eritromicina/farmacologia
Exotoxinas/genética
Feminino
Hospitais
Seres Humanos
Lactente
Leucocidinas/genética
Masculino
Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos
Staphylococcus aureus Resistente à Meticilina/genética
Testes de Sensibilidade Microbiana
Tipagem de Sequências Multilocus
Estudos Retrospectivos
Taiwan/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Bacterial Toxins); 0 (Exotoxins); 0 (Leukocidins); 0 (Panton-Valentine leukocidin); 3U02EL437C (Clindamycin); 63937KV33D (Erythromycin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170707
[St] Status:MEDLINE
[do] DOI:10.1186/s12879-017-2560-0



página 1 de 1214 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde